This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics
Organizer(s): Johnathan R. Whetstine, Jessica K. Tyler and Rab K. Prinjha
Date: January 29 - February 02, 2017
Location: Sheraton Seattle Hotel, Seattle, WA, USA
Sponsored by Incyte Corporation, Merck & Co., Inc., Taylor & Francis and Vertex Pharmaceuticals Incorporated
Summary of Meeting:
Epigenetics impacts human health and disease. Data from a range of diseases (cancer, neurological and immunological disorders) have documented mutations, altered expression and copy number alterations in numerous epigenetic factors (histones, DNA and chromatin modifying enzymes, reader proteins, chromatin modulators and noncoding RNAs). Genome-wide data has also illustrated the relationship between altered epigenetic states (e.g., modified DNA and histones) and disease onset and progression. Therefore, there is a need to discover the molecular mechanisms and interplay between epigenetic regulators. These mechanistic insights will shed light on the impact epigenetic regulators have on cellular homeostasis, while resolving their pathogenic contribution to disease states. This meeting is aimed at interrogating the most current knowledge surrounding the epigenetic events modulating nuclear function (gene expression regulation, enhancer modulation, domains and structural organization as well as cell division and differentiation), while relating this to developmental and disease models. In addition, this meeting will highlight the impact that preclinical and clinical epigenetic therapeutics have on a panel of diseases including cancer and neurological disorders. By presenting these various aspects associated with epigenetics and diverse disease, this unique forum should promote dynamic discussions, interactions and collaborations that will impact our understanding of disease and possible treatment strategies. Opportunities for trainee career development, networking and oral presentations are provided by a “Focus on Junior Scientists” session, a panel discussion and mixer with scientific editors and another with industry scientists.
Scholarship Deadline: September 29 2016
Discounted Abstract Deadline: September 29 2016
Abstract Deadline: October 27 2016
Discounted Registration Deadline: November 30 2016
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Incyte CorporationMerck & Co., Inc.Taylor & FrancisVertex Pharmaceuticals Incorporated
We gratefully acknowledge additional support for this conference from:
March of Dimes Foundation, Grant No. 4-FY16-317
Porvair Sciences Ltd & Chromatrap
Zymo Research Corporation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Epizyme, Inc.

GlaxoSmithKline UK
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found